Pharmerica Corporation (PMC) Holdings Maintained by Swiss National Bank

Swiss National Bank maintained its position in Pharmerica Corporation (NYSE:PMC) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 49,800 shares of the company’s stock at the end of the second quarter. Swiss National Bank owned 0.16% of Pharmerica Corporation worth $1,307,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in the company. Capstone Asset Management Co. boosted its position in shares of Pharmerica Corporation by 0.9% during the 2nd quarter. Capstone Asset Management Co. now owns 16,041 shares of the company’s stock worth $421,000 after purchasing an additional 150 shares in the last quarter. Arizona State Retirement System boosted its position in shares of Pharmerica Corporation by 1.3% during the 1st quarter. Arizona State Retirement System now owns 16,016 shares of the company’s stock worth $375,000 after purchasing an additional 200 shares in the last quarter. Louisiana State Employees Retirement System boosted its position in shares of Pharmerica Corporation by 1.6% during the 2nd quarter. Louisiana State Employees Retirement System now owns 12,700 shares of the company’s stock worth $333,000 after purchasing an additional 200 shares in the last quarter. Tudor Investment Corp ET AL boosted its position in shares of Pharmerica Corporation by 4.7% during the 1st quarter. Tudor Investment Corp ET AL now owns 8,602 shares of the company’s stock worth $201,000 after purchasing an additional 389 shares in the last quarter. Finally, Texas Permanent School Fund boosted its position in shares of Pharmerica Corporation by 1.8% during the 2nd quarter. Texas Permanent School Fund now owns 22,703 shares of the company’s stock worth $596,000 after purchasing an additional 411 shares in the last quarter. 92.15% of the stock is currently owned by institutional investors.

Shares of Pharmerica Corporation (PMC) opened at 29.15 on Friday. The stock has a market cap of $907.18 million, a price-to-earnings ratio of 39.50 and a beta of 0.84. Pharmerica Corporation has a 1-year low of $19.20 and a 1-year high of $29.50. The firm has a 50-day moving average of $29.14 and a 200 day moving average of $26.39.

Pharmerica Corporation (NYSE:PMC) last issued its earnings results on Wednesday, August 2nd. The company reported $0.47 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.47. The firm had revenue of $592.00 million for the quarter, compared to the consensus estimate of $592.96 million. Pharmerica Corporation had a net margin of 1.05% and a return on equity of 10.94%. The business’s revenue was up 13.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.47 earnings per share. Equities research analysts forecast that Pharmerica Corporation will post $1.94 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Pharmerica Corporation (PMC) Holdings Maintained by Swiss National Bank” was originally posted by Stock Observer and is the property of of Stock Observer. If you are reading this article on another website, it was stolen and republished in violation of U.S. and international copyright & trademark law. The legal version of this article can be viewed at https://www.thestockobserver.com/2017/10/13/pharmerica-corporation-pmc-holdings-maintained-by-swiss-national-bank.html.

PMC has been the topic of a number of research analyst reports. Zacks Investment Research cut shares of Pharmerica Corporation from a “buy” rating to a “hold” rating in a research report on Tuesday, July 18th. Credit Suisse Group cut shares of Pharmerica Corporation from an “outperform” rating to a “neutral” rating and increased their price objective for the stock from $29.00 to $29.25 in a research report on Friday, August 4th. They noted that the move was a valuation call. ValuEngine cut shares of Pharmerica Corporation from a “buy” rating to a “hold” rating in a research report on Friday, September 22nd. BidaskClub cut shares of Pharmerica Corporation from a “hold” rating to a “sell” rating in a research report on Monday, July 31st. Finally, UBS AG reissued a “neutral” rating and set a $29.25 price objective (up previously from $26.00) on shares of Pharmerica Corporation in a research report on Thursday, August 3rd. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and one has assigned a buy rating to the stock. The stock has an average rating of “Hold” and a consensus price target of $30.50.

About Pharmerica Corporation

Institutional Ownership by Quarter for Pharmerica Corporation (NYSE:PMC)

Receive News & Ratings for Pharmerica Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharmerica Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply